Calcitonin Gene Related Peptide (CGRP) (8-37), Rat – Catalog #B2026702

Calcitonin Gene Related Peptide (CGRP) (8-37), Rat (Catalog #B2026702) is a rat-derived CGRP fragment supplied as 0.5 mg of lyophilized powder. The (8-37) form—missing the N-terminal 1-7 residues—acts as a competitive antagonist at the CGRP receptor, making it invaluable for studying CGRP-mediated signaling, pain pathways, and vascular responses. This fragment is distinct from full-length CGRP and has become a key tool in migraine and pain research.

Scientific Overview

CGRP is a 37-amino-acid neuropeptide derived from alternative splicing of the calcitonin gene. It exists in two forms: α-CGRP (more prevalent in sensory neurons) and β-CGRP (primarily in endocrine cells). CGRP acts via a G-protein–coupled receptor present in the central and peripheral nervous systems, on blood vessel endothelium, and in immune cells. CGRP is a potent vasodilator and has been implicated in migraine pathophysiology, inflammatory pain, and cardiovascular regulation.

The CGRP (8-37) fragment is an antagonist that competitively blocks CGRP receptor binding. By removing the N-terminal 1-7 amino acids required for full receptor agonism, this fragment provides a research tool to study CGRP's pharmacological mechanisms and to validate CGRP-targeted therapies for migraine and pain conditions.

Key applications include:

• CGRP receptor antagonism and competitive inhibition studies
• Investigation of CGRP's role in migraine and headache pathophysiology
• Pain signaling and neuropeptide research
• Vascular dysfunction and vasodilation mechanism studies
• Validation of CGRP-targeting monoclonal antibodies and small-molecule drugs

Usage & Handling Guidance

Store lyophilized powder at −20°C. Reconstitute in sterile, distilled water or assay buffer immediately before use. Prepare working aliquots to minimize freeze–thaw stress on the peptide.

• Reconstitution: Dissolve in sterile PBS, Tris buffer, or your preferred assay medium. Concentration is experiment-dependent. Request the COA/TDS for specific lot details.
• Antagonism assay: Co-incubate CGRP (8-37) with full-length CGRP in receptor binding or signaling assays to assess competitive antagonism.
• Stability: Peptides may aggregate or oxidize in solution. Use fresh preparations when possible, or store short-term at 2–8°C.

What You Get

• 0.5 mg of rat CGRP (8-37), supplied as lyophilized powder
• A well-characterized CGRP receptor antagonist
• High-purity peptide for receptor studies and competitive inhibition assays
• For research use only (RUO)

Why Researchers Choose It

• Recognized competitive CGRP receptor antagonist with decades of literature support
• Essential tool for dissecting CGRP signaling pathways in pain and migraine research
• Enables validation of therapeutic CGRP blockade mechanisms
• Rat sequence facilitates use in rodent pain models and in vitro systems
• High purity and convenient lyophilized storage format

Frequently Asked Questions (FAQ)

• How does CGRP (8-37) differ from full-length CGRP?
  Full-length CGRP (1-37) is an agonist that activates the CGRP receptor. CGRP (8-37), missing the critical N-terminal 1-7 residues, is a competitive antagonist that blocks receptor binding.
• Is CGRP (8-37) selective for the CGRP receptor?
  Yes, it is selective for the calcitonin-gene-related peptide receptor. However, request the COA for any lot-specific selectivity data.
• Can I use this peptide in vivo (in animals)?
  This product is for research use only (RUO). In vivo efficacy and safety depend on route, dose, and formulation. Consult the literature and request guidance before in vivo studies.
• Should I use rat CGRP (8-37) in rat studies?
  Yes. Rat-derived peptide is ideal for rat models to minimize species mismatch and immune responses.
• How should I store reconstituted peptide?
  Store at 2–8°C for short-term use (hours to days), or freeze at −20°C if longer storage is needed. Avoid repeated freeze–thaw cycles.

References

• Russell FA, King R, Smillie SJ, Kodji X, Brain SD. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014;94(4):1099-142.
• Goodman EC, Iversen LL. Calcitonin gene-related peptide: novel neuropeptide. Life Sci. 1986;38(24):2169-78.
• Brain SD, Grant AD. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev. 2004;84(3):903-34.
• Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338-350.
• Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017;97(2):553-622.